Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

PrecisionPoint Transperineal Access System

The PrecisionPoint Transperineal Access System enables transperineal (TP) biopsies to be carried out in the outpatient setting by both doctors and Urology Nurse Specialists, avoiding the need for general anaesthetic and reducing waiting times. Use of the device delivers safer and more effective prostate biopsies in a timely fashion to optimise cancer diagnostic resources.

  • Reducing hospital admissions
PrecisionPoint™ Transperineal Access System logo

Patients with suspected prostate cancer need prostate biopsies to evaluate their cancer risk. Pre COVID-19, the standard of care for prostate biopsy practice has been outpatient transrectal biopsy (needle inserted via the rectum) under local anaesthetic. This method risks missed diagnosis, infection and sepsis.

Alternatively, transperineal (TP) biopsies (needle inserted through the perineal skin) provide more effective sampling and can virtually eliminate biopsy-related sepsis. However, they are impractical as a primary outpatient procedure because they require complex equipment and a general anaesthetic.

The PrecisionPointTM Transperineal Access System enables TP biopsies to be done without general anaesthetic. The novel needle guide allows for two simple punctures, which can be performed by trained nurses and radiographers in an outpatient setting. By enabling safer, more effective TP biopsies to be carried out under local anaesthetic, it transforms the prostate cancer pathway and improves the patient experience. Across the UK, transrectal biopsies are being abandoned in favour of TP biopsies and the associated savings through reduced use of general anaesthesia.